DR. Carlos Alberto Taboada, MD is a medical oncology internal medicine in Plano, TX with 24 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Carlos Alberto Taboada, MD NPI is 1174565089. The provider is registered as an individual entity type.
The NPPES NPI record indicates the provider is a male.
The provider's business location address is:
3705 W 15TH ST
PLANO, TX
ZIP 75075-753
Phone: (972) 867-3577
Fax: (972) 985-9433
The NPI 1174565089 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.
The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.
- Injection, dexamethasone sodium phosphate, 1mg (HCPCS:J1100)
- Insertion of needle into vein for collection of blood sample (HCPCS:36415)
- Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85025)
- Injection beneath the skin or into muscle for therapy, diagnosis, or prevention (HCPCS:96372)
- Infusion of chemotherapy into a vein up to 1 hour (HCPCS:96413)
- Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour (HCPCS:96367)
- Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour (HCPCS:96365)
- CT scan of abdomen and pelvis with contrast (HCPCS:74177)
- Nuclear medicine study with CT imaging skull base to mid-thigh (HCPCS:78815)
The enumeration date for this NPI number is 6/12/2006 and was last updated on 2/4/2021.